European Medical Solutions SA Overview
European Medical Solutions is a small-cap French-Belgian maker of medical imaging equipment. It sits inside a Belgian listed shell that, until 2021, was the failed allergy biotech ASIT Biotech. Since January 2022 it has housed the medical-imaging division of DMS Group, contributed in kind under a court-approved reorganisation plan. EMS designs and assembles remote-controlled radiography/fluoroscopy (R/F) tables, digital radiography rooms, motorised mobile X-ray units and bone densitometers, mainly at Gallargues-le-Montueux in southern France. It sells through two channels: its own DMS Imaging brand, via 140+ distributors, and white-label OEM agreements with Canon Medical Systems, Fujifilm Healthcare and Carestream Health. Revenue has grown from EUR 35.3M (FY2022) to EUR 49.9M (FY2025), and the EBITDA margin has expanded to 13.0% in H1 2026. Its claimed differentiators are its position as the only European bone-densitometry manufacturer, its ADAM AI software platform, and a carbon-nanotube mobile X-ray (Onyx) awaiting certification. It is effectively an 88%-controlled, thinly traded subsidiary.
The company's own description
In its 2024–2026 releases, EMS describes itself as specialising in the development, design, manufacture and marketing of medical imaging systems, chiefly for digital radiology and bone densitometry. It says its strategy rests mainly on technological innovation and that it offers a complete range of imaging systems internationally. It cites a presence on every continent through a network of more than 140 distributors, subsidiaries and joint ventures (EMS FY2024 results release, 14 Apr 2025, "À propos d'EMS").
Earlier, as DMS Imaging (2022–2023), it called itself the French leader in imaging systems for radiology, bone densitometry, 3D modelling and posturology (DMS Imaging FY2022 results release, 28 Apr 2023).
Independent characterisation
EMS is a niche, mid-tier capital-equipment original equipment manufacturer (OEM) in conventional and digital X-ray imaging.
It is not a modality leader in CT, MRI or ultrasound. It occupies segments that the large conglomerates (Siemens Healthineers, GE HealthCare, Philips) often under-serve or outsource:
-
remote-controlled R/F tables
-
motorised mobile X-ray
-
dual-energy X-ray bone densitometry (DXA)
The business model is a hybrid of two channels.
1. White-label OEM manufacturing (49% of FY2025 revenue). EMS builds R/F tables, radiography systems and bone densitometers that global majors resell under their own brands:
-
Canon Medical Systems: a next-generation R/F system integrating Canon detectors, launched H2 2023.
-
Fujifilm Healthcare: R/F tables and bone densitometry, including the US, Italy and other markets.
-
Carestream Health: radiology, especially in the US.
This channel gives volume and global reach. It also brings customer concentration, lower pricing power and exposure to partners' procurement cycles. That exposure became visible in H1 2026, when OEM radiology sales fell.
2. Own-brand sales under "DMS Imaging" (51% of FY2025 revenue). These go through 140+ independent distributors and direct French hospital tenders, including the UniHA referencing won in July 2022 for four years. They also include government contracts, notably the EUR 11M contract for 120 !M1 Adam mobile units for Ukraine signed in March 2025.
Revenue model mix. The model is overwhelmingly product sales, meaning hardware systems with embedded software. A secondary contribution comes from after-sales service, spare parts and retrofit kits; this is not separately disclosed, although the FY2024 release mentions US revenue "excluding after-sales service".
There is no disclosed subscription or licensing revenue. The ADAM AI software is bundled with hardware, though management describes it as a growth and margin lever.
Value chain position. EMS covers design and R&D, regulatory certification (CE/MDR and FDA registrations), procurement of key components, final assembly and integration, and distribution.
Key components, such as flat-panel detectors, X-ray tubes and generators, are sourced externally. The August 2025 entry of detector specialists InnoLux and InnoCare Optoelectronics into the parent's capital points to a vertical sourcing partnership.
Component supply tension (Stratos and Stratos DR, H1 2025) has been a recurring operational constraint.
Customer types:
-
public and private hospitals
-
imaging centres and radiology practices
-
clinics, including orthopaedics and rheumatology
-
governments and development-finance-backed tenders: World Bank-financed tables in 2021 via Groupe FSE, and Ukraine in 2025–2026, financed by France's Ukraine economic-resilience fund with AFD
-
global OEMs
End markets:
-
general diagnostic radiology (fluoroscopy, radiography)
-
mobile bedside imaging (ICU, emergency departments, paediatrics)
-
surgical imaging (mobile C-arms)
-
osteoporosis diagnosis and body composition (DXA)
-
women's health (mammography, Serenys range, per aggregator catalogue)
-
3D stereo-radiography and posturology (AXS Medical heritage)
Historical business (ASIT Biotech, 1997–2021)
| Product | Indication | Status |
|---|---|---|
| gp-ASIT+™ | Grass-pollen allergic rhinitis | Lead; Phase III |
| hdm-ASIT+™ | House-dust-mite allergy | Earlier stage |
| pnt-ASIT+™ | Peanut allergy | Preclinical |
ASIT biotech was a clinical-stage biopharmaceutical company. Its ASIT+™ platform produced short-course allergy immunotherapy (AIT) products made of highly purified natural allergen fragments, without adjuvant. Its pipeline was:
The company never generated material product revenue. Its value collapsed after the confirmatory Phase III of gp-ASIT+ failed in November 2019. That failure led to judicial reorganisation in 2020–2021 and to the reverse takeover by DMS's imaging division.
Strategy
Stated strategy
| Version | Revenue target | EBITDA target |
|---|---|---|
| Original (DMS Imaging FY2022 results) | At least EUR 60M | 14% margin |
| Raised (DMS Group website and Euroland Corporate, 2025–2026) | At least EUR 70M | 14% margin, also expressed as about EUR 10M |
#Imaging 2027. This plan was first announced by DMS Group in October 2022. Its targets have evolved:
The plan was designed to run in two phases, with operating leverage expected from 2025.
The pillars, as described in company releases from 2024 to 2026, are:
-
Product-mix broadening and innovation: Platinum Neo, the !M1 and Onyx mobiles, ADAM AI, and new surgical C-arms and DR rooms.
-
Rebalancing between own brand and white label. Own brand moved from 42% in FY2023 to 51% in FY2025.
-
International expansion, especially North America and the Middle East.
-
Industrial value-chain control, from design to assembly at Gallargues, with the Swedish site integrated from 2026 and capacity sized for EUR 70M of revenue.
-
A "pure player" profile in industrial radiology with a broad range.
#Imaging 2030 (in preparation). Funded by the 2025 capital increase and the EIB line, this plan has four priorities per the DMS 2025 annual report, including:
-
strengthening industrial synergies
-
finalising new solutions
-
AI (ADAM)
-
carbon-nanotube technology
Initiatives in the last 24 months
| Date | Initiative | Detail |
|---|---|---|
| 2024 (ECR) | ADAM AI multiplatform | AI software to be deployed on all systems; integrated into the !M1 mobile |
| 2,024 | US agreements | Medlink Imaging and JPI Healthcare agreements for motorised mobile units; FDA registrations in progress; first US sales expected from Q2 2025 |
| Late 2024 | Onyx launch | Carbon-nanotube mobile unveiled; certification delayed by notified-body backlogs, still pending at Sep 2025 |
| 2,024 | Cost restructuring | Strong reduction of operating and overhead costs from H2 2024; reverse split to cut securities-administration costs; liquidation of the Spanish subsidiary |
| Mar 2025 | Ukraine programme | EUR 11M, 120 !M1 Adam units; positions EMS as a preferred partner for Ukrainian health reconstruction |
| Aug 2025 | Parent equity raise | EUR 6.9M from InnoLux and InnoCare (detector-industry strategic investors), Bpifrance and NextStage AM |
| Mar–Jun 2026 | EIB financing (parent) | Line of up to EUR 20M in three tranches under InvestEU. The first EUR 4M was drawn in June 2026, with 6-year maturity, a 2-year grace period and a 5% fixed rate (3% capitalised), plus 1,205,838 warrants (BSA) issued to the EIB. Uses: new digital DR rooms, surgical mobile C-arms, AI-assisted interpretation, industrial capacity; spending mainly in France, 2026–2030. |
| Apr 2026 | Regulatory | European MDR certification for the STRATOS bone-densitometer range |
| 2,026 | Operational efficiency | Production-process improvement, purchasing optimisation and contract renegotiation; H1 2026 personnel costs −9% and external costs −6% |
ESG commitments: none formally disclosed.
Guidance
FY2026: a "pause" in revenue growth, with profitability expected to keep improving. Q3 2026 activity reflects the market slowdown (EMS H1 2026 results, 14 Sep 2026).
Long term: management aims to outperform the medical imaging market, which it describes as structurally supportive. The Imaging 2027 targets (EUR 70M revenue, 14% EBITDA margin) were reiterated by the parent in April 2026. Management did, however, acknowledge limited short-term visibility.
Products & Services
Pricing is not publicly disclosed for any product. Specifications are limited to what company releases and catalogue aggregators disclose.
Radiology division
| Product | Category | Description and capabilities | Target customer | Launch / latest version | Channel |
|---|---|---|---|---|---|
| Platinum Neo | Remote-controlled R/F table (flagship) | Next-generation high-end R/F system; described as rethinking the R/F workflow; ADAM AI integrated; ramp-up from 2023; one-off launch costs hit FY2023 margins | Hospitals and large imaging centres | Ramp from 2023; "nouvelle génération" Platinum referenced in FY2023 | Own brand and OEM; South America Platinum order in H1 2026 |
| Optima dRF | R/F system | Robust digital R/F solution, positioned below Platinum | Mid-size hospitals and clinics | — | Own brand and OEM |
| Canon-detector R/F system | R/F (OEM) | Next-generation R/F system developed by EMS integrating Canon Inc. detector technology, for Canon Medical Systems Europe | Canon's customer base | H2 2023 | OEM (Canon) |
| Xavion | Radiology solution | Radiology system launched in 2024; specifications not disclosed | — | 2,024 | Own brand |
| !M1 / !M1 Adam | Motorised mobile X-ray | From Solutions For Tomorrow (Sweden); positioned as uniquely compact, ergonomic and powerful; ADAM integrated in 2024; holds European marketing authorisations; FDA registrations in progress (2025); 120 units for Ukraine | ICU, emergency, wards; US market (more than 1,200 motorised mobiles sold annually, per EMS) | SFT heritage; ADAM version 2024 | Own brand; OEM/partners (Medlink Imaging, JPI Healthcare in the US) |
| Onyx | Mobile X-ray (carbon-nanotube tube) | New-generation carbon-nanotube (CNT) X-ray tube with zero-gravity arm; for ICU, emergency and paediatrics; SFR Innovation Prize at JFR 2024; offered to existing OEM clients and other manufacturers; first installs were planned for Q1 2025 but still awaiting certification as of Sep 2025 | Hospitals; OEMs | Unveiled Nov/Dec 2024 (JFR); certification pending | OEM and own brand |
| Digital radiography rooms (chest / bone rooms) | Fixed DR | Floor-mounted and ceiling-suspended tube stands | Imaging centres, hospitals | — | Own brand and OEM |
| Ambulatory radiography | Fixed / outpatient DR | Outpatient radiography configurations | Private practices | — | Own brand |
| DR retrofit kits | Upgrade kits | Convert analogue or CR rooms to digital radiography | Installed-base owners | — | Own brand |
| EVO R+ FP | Mobile C-arm (surgical) | Flat-panel mobile C-arm for operating rooms (aggregator catalogue). The EIB-funded programme (2026–2030) targets new surgical mobile C-arms. | Operating theatres, orthopaedics | — | Own brand |
| Serenys DR / DR C / DR DBT | Mammography | Digital mammography, including a digital breast tomosynthesis (DBT) variant (aggregator catalogue) | Women's-health centres | — | Own brand |
| ADAM / ADAM AI | Imaging software platform | Workflow and image-processing software, AI-enhanced since 2024 (multiplatform); installed on more than 500 remote-controlled tables worldwide; to be deployed across all systems; includes cybersecurity features | All EMS system buyers; OEMs | ADAM platform 2021 (referenced Feb 2021); ADAM AI 2024 | Bundled |
| AXS Medical solutions | 3D stereo-radiography and posturology | 3D modelling of the musculoskeletal system and postural analysis (AXS Medical heritage) | Orthopaedics, spine, sports medicine | — | Own brand |
Bone densitometry division
| Product | Category | Description and capabilities | Target customer | Launch / latest version | Channel |
|---|---|---|---|---|---|
| Stratos DR | DXA bone densitometer | X-ray bone densitometry for bone-mineral-density measurement and fracture-risk assessment; component supply tensions in H1 2025; European MDR certification obtained for the STRATOS range (DMS Group, 7 Apr 2026) | Rheumatology, gynaecology, osteoporosis centres | MDR certified Apr 2026 | Own brand and OEM (Fujifilm) |
| Stratos (and Stratos 3D-DX per aggregator) | DXA | Full-body DXA, body-composition analysis; 3D-DX variant (aggregator catalogue) | As above | — | Own brand and OEM |
| Medix series | Bone densitometry | Fracture-risk and body-composition systems (aggregator catalogue) | Clinics | — | Own brand |
| Ultrasound bone densitometers | Quantitative ultrasound | Ultrasound-based assessment for bone micro-architecture reconstruction (Euronext/Cofisem company profile) | Primary care, screening | — | Own brand |
Bone densitometry: market position notes
-
Exports accounted for 97% of bone-densitometry revenue in FY2022, largely through the Fujifilm Healthcare manufacturing agreement (DMS Imaging FY2022 results).
-
EMS states it is the only European bone-densitometry manufacturer and that its two main competitors are American (EMS FY2024 results, tariff commentary).
Services
After-sales service, maintenance, spare parts and training are provided directly in France and via distributors and OEMs internationally. Revenue is not separately disclosed. US revenue in FY2024 was EUR 2.6M excluding after-sales service.
Legacy ASIT pipeline (discontinued)
| Product | Indication | Last status |
|---|---|---|
| gp-ASIT+™ | Grass-pollen allergic rhinitis | Confirmatory Phase III (about 650 patients) failed its primary endpoint in Nov 2019; effect was roughly half of what was expected |
| hdm-ASIT+™ | House-dust-mite allergy | Phase IIa readiness (2016); to be partnered (2019) |
| pnt-ASIT+™ | Peanut allergy | Preclinical / first-in-man batch planned for H1 2019 |
All were abandoned with the 2020–2021 reorganisation.
Financial Narrative
Basis:
-
FY2021 is the "combined" imaging division of DMS Group, unaudited as a consolidated perimeter (DMS Imaging FY2022 results).
-
FY2022–FY2025 are audited consolidated IFRS figures for DMS Imaging / EMS.
-
Sources by year: FY2022 results release (28 Apr 2023); FY2023 annual report and FY2024 results (comparatives); FY2024 results (14 Apr 2025); FY2025 results (13–14 Apr 2026, as reported by ABC Bourse, 15 Apr 2026).
-
ASIT Biotech's own FY2021 standalone accounts (a shell in reorganisation) are not comparable and are excluded.
Income statement
Notes on the income statement:
Gross profit: is not publicly disclosed. Euroland Corporate estimates the parent's FY2025 gross margin at close to 40%.
D&A for FY2021, FY2022 and FY2025: is derived as EBITDA minus ROC. FY2023 and FY2024 are reported.
FY2025 operating income: is derived as ROC plus other items. The FY2024 figure as reported is 1.3.
FY2022 one-offs: a EUR −3.0M IFRS 2 listing charge, a EUR −1.6M impairment of an R&D tax credit following the change of control, and EUR −0.5M of other provisions, all non-cash. EBITDA was also adjusted for EUR 0.513M of contribution-related costs.
FY2024 and FY2025 other operating items: mainly reflect Solutions For Tomorrow integration costs.
FY2021 financial result: is not disclosed separately.
Margins and growth
ROC margins and net margins are derived.
Interim trend
Sources: EMS H1 2025 results (29 Sep 2025) and H1 2026 results (14 Sep 2026). The H1 2024 operating income of 0.4 is derived. H1 2025 D&A is shown as 1.0 in the H1 2025 release and as 1.1 in the H1 2026 comparative; 1.1 is used here.
Per-share data
EPS (basic and diluted): is not publicly disclosed in sources reviewed. An indicative FY2025 EPS is about EUR 0.43, derived from net income of EUR 1.8M over about 4.23M post-consolidation shares (1.49bn pre-split shares ÷ 352). HALO Technologies shows a P/E of 12.0 at EUR 3.90, which implies trailing EPS of about EUR 0.33, likely on a different period or share basis.
Dividends: none paid in any year reviewed; no dividend policy disclosed.
Balance sheet
Notes and source conflicts:
FY2022 bank loans: include EUR 5.9M of French state-guaranteed loans (PGE). In FY2024, bank loans were mainly state-guaranteed.
FY2023 net debt: is not disclosed directly. The FY2024 release describes it as stable versus the end of 2023, implying roughly EUR 11M.
FY2025 conflict: the FY2025 release (via ABC Bourse) gives cash of EUR 5.8M and net debt of EUR 9.0M. The H1 2026 release restates end-2025 cash as EUR 4.9M and net debt as EUR 10.0M. Both are shown; the difference is unexplained in sources and may reflect cash classification or a perimeter adjustment.
Equity: FY2021 and FY2022 equity is group share. FY2023 total equity is EUR 9.892M; group share is EUR 9.816M.
Goodwill and intangibles: are not publicly disclosed in sources reviewed.
Source: EMS H1 2026 results.
Working capital. The FY2022 balance sheet shows inventories of EUR 13.0M plus receivables of EUR 6.1M, less payables of EUR 9.4M. That gives trade working capital of about EUR 9.7M, or 27% of revenue (derived). Later years are not disclosed in sources reviewed.
Cash flow
Notes:
-
FY2022 is from the DMS Imaging FY2022 results release.
-
For FY2023–FY2025, cash-flow statements were not available in sources reviewed. HALO Technologies reports trailing operating cash flow of about EUR 5M and a free-cash-flow return of 21.3% (aggregator).
-
No buyback programme is disclosed.
Ratios
All ratios are derived by the analyst unless stated.
Notes:
FY2022 ROA: is based on total assets of EUR 39.9M.
FY2025 net debt / EBITDA: is 1.7x on EUR 9.0M net debt, or 1.9x on the restated EUR 10.0M.
Interest coverage: HALO Technologies shows 4.9x.
ROIC: is not computed for lack of invested-capital detail. HALO Technologies shows 8.4%.
Current ratio: is not disclosed for later years. For FY2022, current assets of EUR 23.3M are known but current liabilities are not split. HALO Technologies shows a quick ratio of 0.8x.
Cash conversion cycle: is not publicly disclosed. Inventory is the dominant working-capital item (EUR 13.0M in FY2022, about 135 days of revenue, derived).
Commentary on trends, inflections and drivers
Revenue. Revenue dipped in FY2022 (−3%) because of a demanding FY2021 base, which included an exceptional EUR 6M World Bank-financed table contract via Groupe FSE. It was also hit by the loss of Russian, Ukrainian and Belarusian sales, which had been about 4% of FY2021 revenue.
Growth then resumed for three consecutive years:
FY2023 (+15%): driven by OEM volume, including the 96-table Fujifilm Italy order, and the Platinum Neo ramp-up.
FY2024 (+11%): driven by Africa (+65%), Asia (+67%) and own-brand distributor growth. This came despite a four-week ransomware outage in Q1 2024.
FY2025 (+11%): driven by North America (+71% to EUR 6.9M, via Carestream and Fujifilm white-label sales and first !M1 shipments through Medlink), the Middle East (+95%) and the start of Ukraine deliveries. Europe declined 5%.
Inflection in 2026. H1 2026 revenue fell 6%, the first decline since FY2022, as European OEM demand weakened. Management explicitly guides FY2026 as a "pause" in growth. It flags that Q3 2026 activity reflects the market slowdown.
Profitability. The structural story is margin expansion. Reported EBITDA margin rose from 5.9% in FY2022 to 10.8% in FY2025, and to 13.0% in H1 2026, achieved on lower revenue. The drivers cited are:
-
higher gross margin: a target of +2 to +3 points was set for 2024, and own-brand mix is rising
-
cost discipline: H1 2026 personnel costs fell 9% and external costs 6%
-
operating leverage
ROC moved from breakeven to EUR 3.0M. The 14% EBITDA-margin target of the Imaging 2027 plan was effectively reached in H1 2026 (13.0%), one year early on a half-year basis.
Net income turned positive in FY2024 after FY2022's non-cash reverse-takeover charges.
Balance sheet. The capital base is thin: equity of EUR 12–13M against total assets of roughly EUR 40M or more. Leverage is moderate but rising again. Net debt rose from EUR 10.0M (restated end-2025) to EUR 12.6M at June 2026, while cash fell to EUR 3.1M. Factoring is a meaningful financing tool.
The parent's EUR 6.9M equity raise (2025) and EIB line (2026) sit at DMS Group level. How much of this flows down to EMS, for example through intra-group current accounts, is not disclosed and is a key monitorable for minority shareholders.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment revenue (EUR Mn)
| Segment revenue (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Radiology | 31.2 | 29.3 | 31.5 | 35.0 | 39.0 |
Bone densitometry | 5.0 | 6.0 | 9.0 | 10.1 | 10.9 |
Total group revenue | 36.3 | 35.3 | 40.6 | 45.1 | 49.9 |
Segment Margins & Growth (%) and Revenue by Segment (%)
| Segment metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Radiology YoY growth (%) | -6 | 8 | 11 | 11 |
Bone densitometry YoY growth (%) | 21 | 50 | 12 | 8 |
Radiology share of revenue (%) | 83 | 78 | 78 | 78 |
Bone densitometry share of revenue (%) | 17 | 22 | 22 | 22 |
Segment revenue, half-year (EUR Mn)
| Segment revenue, half-year (EUR Mn) | H1 2025 | H1 2026 |
|---|---|---|
Radiology | 18.8 | 17.1 |
Bone densitometry | 4.7 | 5.0 |
Total | 23.5 | 22.1 |
Q1 revenue (EUR Mn)
| Q1 revenue (EUR Mn) | Q1 2024 | Q1 2025 |
|---|---|---|
Radiology | 6.8 | 8.5 |
Bone densitometry | 2.6 | 2.3 |
Total | 9.4 | 10.9 |
Revenue by Segment (%)
| Channel mix (% of revenue) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Own brand (DMS Imaging, via distributors) | 42 | 48 | 51 |
White label (OEM agreements) | 58 | 52 | 49 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansIncome statement (EUR Mn)
| Income statement (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Revenue | 36.3 | 35.3 | 40.6 | 45.1 | 49.9 |
Revenue growth (%) | — | -2.8 | 15.0 | 11.1 | 10.6 |
EBITDA (reported) | 2.5 | 2.1 | 2.6 | 4.4 | 5.4 |
EBITDA adjusted (ex contribution costs) | 2.5 | 2.6 | 2.6 | 4.4 | 5.4 |
Depreciation, amortisation and provisions | 2.2 | 2.3 | 2.7 | 2.6 | 2.4 |
Current operating income (ROC) | 0.3 | -0.2 | -0.1 | 1.7 | 3.0 |
Other operating income and expenses | -0.2 | -5.1 | 0.0 | -0.5 | -0.5 |
Operating income | 0.0 | -5.3 | -0.1 | 1.3 | 2.5 |
Financial result | — | -0.3 | -0.6 | -0.5 | -0.6 |
Net income, group share | -0.2 | -5.6 | -0.7 | 0.5 | 1.8 |
Margins (%)
| Margins (%) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Gross margin | — | — | — | — | 40 |
EBITDA margin (reported) | 6.8 | 5.9 | 6.4 | 9.6 | 10.8 |
EBITDA margin (adjusted) | 6.8 | 7.3 | 6.4 | 9.6 | 10.8 |
Operating (ROC) margin | 0.8 | -0.6 | -0.2 | 3.8 | 6.0 |
Net margin | -0.6 | -15.9 | -1.7 | 1.1 | 3.6 |
Growth metric
| Growth metric | Value |
|---|---|
Revenue CAGR FY2021–FY2025 | 8.3% (derived) |
Revenue CAGR FY2022–FY2025 | 12.2% (derived) |
EBITDA CAGR FY2022 (adjusted) to FY2025 | 27.6% (derived) |
Income Statement and Margin Analysis (%)
| Half-year P&L (EUR Mn) | H1 2024 | H1 2025 | H1 2026 |
|---|---|---|---|
Revenue | 21.9 | 23.5 | 22.1 |
EBITDA | 2.0 | 2.4 | 2.9 |
EBITDA margin (%) | 8.9 | 10.0 | 13.0 |
D&A and provisions | 1.4 | 1.1 | 1.0 |
Current operating income | 0.6 | 1.3 | 1.8 |
Other operating items | -0.2 | -0.2 | -0.4 |
Operating income | 0.4 | 1.1 | 1.5 |
Financial result | — | -0.1 | -0.2 |
Net income | — | 1.0 | 1.1 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansPer-share data (EUR)
| Per-share data (EUR) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Dividend per share | 0 | 0 | 0 | 0 | 0 |
Balance Sheet
| Balance sheet (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Total assets | 36.3 | 39.9 | — | — | — |
Non-current assets | 12.3 | 12.4 | — | — | — |
Inventories | 11.6 | 13.0 | — | — | — |
Trade receivables | 6.5 | 6.1 | — | — | — |
Cash and equivalents | 2.4 | 4.2 | 4.2 | 4.6 | 5.8 |
Gross financial debt (ex IFRS 16) | 8.2 | 9.9 | — | 15.8 | 14.8 |
of which bank loans | — | 6.7 | — | 11.0 | 9.0 |
of which factoring debt | — | 1.3 | — | 3.9 | 5.3 |
of which repayable advances | — | 1.9 | — | 0.9 | 0.5 |
Lease liabilities (IFRS 16) | 5.3 | 4.9 | — | — | — |
Net financial debt (ex IFRS 16) | 5.8 | 5.7 | — | 11.1 | 9.0 |
Total equity | 10.8 | 10.6 | 9.9 | 10.3 | 12.1 |
Trade payables | 6.6 | 9.4 | — | — | — |
Balance Sheet, 30 June 2026 Details
| Balance sheet, 30 June 2026 (EUR Mn) | Value |
|---|---|
Total equity | 13.1 |
Cash | 3.1 |
Gross financial debt (ex IFRS 16) | 15.7 |
of which bank debt | 12.8 |
of which factoring | 2.6 |
of which conditional advances | 0.3 |
Net financial debt (ex IFRS 16) | 12.6 |
Cash flow (EUR Mn)
| Cash flow (EUR Mn) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Cash flow from operations (after working capital) | — | 2.3 | — | — | — |
Self-financing capacity (MBA) | — | 1.7 | — | — | — |
Change in working capital (positive = inflow) | — | 0.6 | — | — | — |
Capex (investing flows) | — | -1.0 | — | — | — |
Free cash flow | — | 1.3 | — | — | — |
New borrowings | — | 3.0 | — | — | — |
Debt repayments | — | -2.7 | — | — | — |
Net change in cash | — | 1.8 | — | — | — |
Dividends paid | 0 | 0 | 0 | 0 | 0 |
Share buybacks | 0 | 0 | 0 | 0 | 0 |
Returns & Leverage Ratios (%) and Financial Ratios (x)
| Ratio | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
ROE (%) | -1.9 | -52.8 | -7.1 | 4.9 | 14.9 |
ROA (%) | -0.6 | -14.0 | — | — | — |
Net debt / EBITDA (x) | 2.3 | 2.7 | — | 2.5 | 1.7 |
Net debt / equity (%) | 54 | 54 | — | 108 | 74 |
Interest coverage, ROC / financial result (x) | — | -0.7 | -0.2 | 3.4 | 5.0 |
Asset turnover (x) | 1.00 | 0.88 | — | — | — |
Region share of revenue (%)
| Region share of revenue (%) | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
Europe | 61.3 | 58 | 50 |
North America | — | 9 | 14 |
Americas (North and South) | 18.4 | — | — |
Middle East | 4.5 | 4 | 8 |
Asia / Asia-Pacific | 7.1 | 10 | 8 |
Africa | 3.9 | 5 | — |
Oceania | 1.1 | — | — |
Rest of world / other | 3.7 | — | 20 |
Region revenue (EUR Mn)
| Region revenue (EUR Mn) | FY2024 | FY2025 |
|---|---|---|
North America | 4.0 | 6.9 |
Middle East | 1.9 | 3.8 |
United States (ex after-sales service) | 2.6 | — |
Europe | 26.2 | 25.0 |
Capital Markets
| Item | Value | Source |
|---|---|---|
Share price | EUR 3.90 (14–18 Sep 2026) | ABC Bourse; HALO Technologies |
Market capitalisation | About EUR 17.1M | HALO Technologies, 18 Sep 2026 |
Shares outstanding | About 4.23M post-consolidation (derived from about 1.49bn pre-split ÷ 352) | Hargreaves Lansdown / EODHD pre-split share count; derived |
52-week range | EUR 3.40 to 5.75 | HALO Technologies |
Free float | About 12% (derived from the 88.33% DMS stake at Jan 2022) | Derived |
Liquidity | Extremely low; HALO shows 12-month traded value of about USD 110 (aggregator figure, likely data-quality-limited) | HALO Technologies |
Price Performance Details
| Price performance (%) | 1 year | Year to date (2026) | 1 month |
|---|---|---|---|
ALEMS total price change | -14.95 | -13.68 | 8.6 |
Valuation Multiple Details
| Valuation multiple (x) | EMS (analyst-derived) | HALO Technologies (aggregator) |
|---|---|---|
P/E (FY2025) | 9.5 | 12.0 |
EV/EBITDA (FY2025) | 5.5 | 6.7 |
EV/Sales (FY2025) | 0.59 | — |
P/B (June 2026) | 1.3 | — |
Capital Markets — Dividends
| Item | Status |
|---|---|
Dividends | None paid (2016–2025); no stated policy |
Buyback authorisations | None disclosed |
Credit ratings (Moody's, S&P, Fitch) | Not rated |
Action by Date
| Date | Action |
|---|---|
May 2016 | IPO at EUR 7.00 |
Jul 2018 | EUR 12M convertible bond |
2021–2022 | Creditor debt-to-equity conversions and massive issuance to DMS for the contribution |
1 Sep 2023 | Transfer to Euronext Growth |
31 Dec 2024 | 352:1 reverse split |
Analyst Conclusions
Management guidance
FY2026: a pause in revenue growth, with continued profitability improvement driven by efficiency actions. Q3 2026 activity reflects the market slowdown (EMS H1 2026 results, 14 Sep 2026).
Imaging 2027: at least EUR 70M revenue and a 14% EBITDA margin (about EUR 10M EBITDA), reiterated at parent level in April 2026.
Long term: outperform the medical imaging market.
Consensus: none available.
Implied arithmetic. If FY2026 revenue is roughly flat at about EUR 48–50M (analyst illustration, not guidance), the 2027 target would require growth of about 40% in one year. That looks unachievable organically. The 14% margin goal, by contrast, looks within reach given H1 2026's 13.0%.
Bull case
-
Margin engine is proven. EBITDA margin more than doubled in three years (5.9% to 13.0%). If revenue resumes even mid-single-digit growth, operating leverage could push EBITDA toward EUR 6.5–7M, making an EV/EBITDA of about 5.5x look cheap.
-
Mix shift de-risks the model. Own brand rose from 42% to 51% of sales, North America and the Middle East are scaling, and bone densitometry (unique European position, MDR-certified) is growing counter-cyclically.
-
New product cycle funded. Onyx certification, US mobile sales and EIB-funded DR rooms and C-arms (2026–2030), backed by detector-maker shareholders, could restore double-digit growth from 2027.
Bear case
-
Growth has stalled. Revenue fell 6% in H1 2026, management guides a pause, European OEM demand is weakening, and the EUR 70M 2027 target is effectively out of reach.
-
Balance sheet is tightening. Cash halved to EUR 3.1M in six months, net debt rose to EUR 12.6M, and new funding sits at the parent. Minority holders depend on intra-group decisions.
-
Minority-shareholder structure is unattractive. About 88% is controlled by DMS Group, the float is minimal, liquidity is near zero, and the shared CEO raises conflict risk. Value creation may accrue mainly to the parent, and any eventual squeeze-out could be priced opportunistically.
Catalysts and monitorables (next 12 months)
| Expected timing | Catalyst / monitorable |
|---|---|
| Around 20 Oct 2026 | Q3 2026 revenue: magnitude of the slowdown; delivery of the final two Ukraine batches |
| Jan 2027 | FY2026 revenue: confirmation of the "pause"; H2 trajectory |
| Apr 2027 | FY2026 results: EBITDA margin vs 14% target; net debt and cash; any Imaging 2030 targets |
| Ongoing | Onyx CE/MDR certification and first installations; FDA clearances for !M1 in the US |
| Ongoing | Follow-on Ukraine or reconstruction orders; Middle East tenders |
| Ongoing | OEM order trends (Canon, Fujifilm, Carestream); any partner change |
| Ongoing | Parent actions: EIB tranches B and C, intra-group financing to EMS, any merger or squeeze-out proposal |
| Ongoing | US tariff developments affecting EU-made medical devices |
Analyst verdict
The listed vehicle once called ASIT Biotech is a cautionary tale and a modest industrial success story at the same time. As a biotech, it destroyed almost all IPO capital: a single-asset allergy immunotherapy failed its confirmatory Phase III in November 2019, and judicial reorganisation followed. The 2022 reverse takeover by DMS Group's imaging division turned the shell into a real business. European Medical Solutions is a profitable, specialised X-ray and bone-densitometry manufacturer with EUR 49.9M of revenue, EUR 5.4M of EBITDA and EUR 1.8M of net income in FY2025.
Operationally, the record since 2022 is credible. Revenue compounded at about 12% a year from FY2022 to FY2025, the own-brand share passed 50%, and EBITDA margin expanded to 13% in H1 2026 even as revenue fell. The franchise is defensible in its niches: R/F tables, motorised mobiles, and DXA, where EMS claims to be Europe's only manufacturer. Tier-1 OEM partners validate the technology, and Onyx and ADAM AI provide genuine optionality.
The investment case for outside shareholders is much weaker than the operating story, for three reasons:
Growth has paused,: making the EUR 70M 2027 target unrealistic without acquisitions.
Liquidity has deteriorated,: with cash at EUR 3.1M and net debt at EUR 12.6M, while new funding sits at the parent.
The structure is unfavourable: An approximately 88% controlling shareholder with a shared CEO, a free float of about 12% and negligible trading volume mean the valuation discount may persist indefinitely.
At about 5.5x EV/EBITDA and about 9.5x trailing earnings (analyst-derived), the shares are optically inexpensive. That cheapness reflects real governance and liquidity constraints rather than mispricing alone.
Verdict: a fundamentally improving but strategically captive micro-cap. It is most interesting as a call option on Onyx and US execution, or on an eventual parent consolidation. Prefer exposure via the parent, DMS Group (ALDMS), which captures the same operations with better liquidity and direct access to the new financing.
Sources consulted (principal)
ASIT Biotech era:
-
Euronext listing release (11 May 2016)
-
IPO releases (14 Apr, 28 Apr and 10 May 2016)
-
H1 2016 and H1 2018 reports; FY2016 results (11 Apr 2017)
-
Edison Investment Research notes (2018–2019)
-
Bolero/De Tijd (25 Nov 2019); Test-Achats (27 Nov 2019)
-
Business Wire PRJ releases (11 Feb and 26 May 2020)
-
AMF/DILA-filed releases (11 Jan, 15 Jan, 9 Feb, 25 Feb, 16 Apr, 14 Sep and 9 Nov 2021)
-
DMS Group AGM agenda (17 Dec 2021)
DMS Imaging / EMS:
-
FY2021 results release (DMS Imaging)
-
H1 2022 results (30 Sep 2022)
-
FY2022 revenue (20 Jan 2023) and FY2022 results (28 Apr 2023)
-
Euronext Growth transfer releases and information document (May–Aug 2023)
-
H1 2023 results (21 Sep 2023)
-
FY2023 results (18 Apr 2024) and FY2023 annual report
-
Rename release (13 Jun 2024)
-
H1 2024 results (7 Oct 2024)
-
FY2024 results (14 Apr 2025)
-
Q1 2025 revenue (22 Apr 2025)
-
H1 2025 results (29 Sep 2025)
-
FY2025 results (14–15 Apr 2026, via ABC Bourse)
-
H1 2026 revenue (Idéal Investisseur, Jul 2026) and H1 2026 results (ABC Bourse, 14 Sep 2026)
-
Euronext company pages (Cofisem data)
DMS Group (parent):
-
FY2025 revenue (19 Jan 2026) and FY2025 results (14 Apr 2026)
-
EIB financing releases (27 Mar and 1 Jun 2026)
-
Q2 2026 revenue; H1 2026 results (14 Sep 2026)
-
Investor presentation (22 Apr 2026)
-
Euroland Corporate notes; Zonebourse / Option Finance
Aggregators (flagged where used): HALO Technologies; Fintel; EODHD; roic.ai; Hargreaves Lansdown; Dealroom.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure | Background |
|---|---|---|---|
Samuel Sancerni | Chairman & CEO (PDG) of EMS and DMS Group | PDG of DMS Imaging since the 2022 contribution; Chairman of DMS Group since 2022; more than 25 years at DMS Group (DMS 2025 annual report) | Career within DMS Group; education and age not publicly disclosed |
Valérie Pugnaloni | Administrative & Finance Director (CFO) | — | — |
Swan Tuffery | Director, Research & Development | — | — |
Nathalie Caire Richard | Chief Human Resources Officer | — | — |
David Terreehorst | Purchasing Manager | — | — |
Jean-Yves Barbara | Head of Investor Relations | — | — |
“—” = not publicly disclosed.
Executive Leadership Team — Thierry Legon
| Name | Role | Period |
|---|---|---|
Thierry Legon | Founder; CEO (administrateur délégué) | 1997 to about 2018/19 |
Béatrice De Vos | Chair of the Board | At IPO, 2016 |
Michel Baijot | CEO | 2019–2020, including the PRJ filing |
Frank Hazevoets | Managing Director & CEO | 2021, through plan homologation |
Vincent Bille | VP CMC | 2019 |
Major Shareholders
| Holder | Stake | Source |
|---|---|---|
Diagnostic Medical Systems SA (DMS Group) | 88.33% (Jan 2022); current figure not disclosed in sources reviewed | DMS Imaging FY2021 results release |
Former ASIT creditors who converted claims into shares under the PRJ | Part of the free float; size not disclosed | ASIT reorganisation releases, 2021 |
Free float | About 11.7% at Jan 2022 (derived) | Derived |
Competitive Landscape
Competitors by Segment
| Segment | Competitor | Positioning vs EMS |
|---|---|---|
R/F tables and DR rooms | Siemens Healthineers | Global leader; broad portfolio; scale and service network far beyond EMS |
R/F, DR, mobile X-ray | GE HealthCare | Global leader in X-ray and mobile; also a bone-densitometry (Lunar DXA) competitor |
R/F, DR, mobile | Philips | Global diagnostic X-ray player |
R/F, DR, mobile | Canon Medical Systems | Also an EMS OEM customer (co-opetition) |
DR, mobile, R/F | Fujifilm Healthcare | Also EMS's largest OEM partner (co-opetition) |
DR, mobile | Carestream Health | Also an EMS OEM partner (co-opetition) |
R/F tables, DR | Shimadzu | Strong in R/F and fluoroscopy (Japan) |
DR, mobile, R/F | Villa Sistemi Medicali (Italy); Italray (Italy) | Direct European mid-tier competitors in R/F and radiography rooms |
DR / imaging IT | Agfa HealthCare | DR rooms and mobiles in Europe |
Mobile X-ray | Samsung (Samsung Medison / NeuroLogica); Mindray; United Imaging | Aggressive Asian competitors in mobile DR |
Bone densitometry (DXA) | Hologic | US leader in DXA; one of the "two main American competitors" referenced by EMS |
Bone densitometry (DXA) | GE HealthCare (Lunar) | The other main US DXA competitor |
CNT X-ray sources | Micro-X (Australia) | Carbon-nanotube mobile X-ray pioneer; direct technology competitor to Onyx |
Peer Comparison FY2025
| Benchmark (latest FY) | EMS (FY2025) | Siemens Healthineers (FY2024) | GE HealthCare (FY2024) | Hologic (FY2024) |
|---|---|---|---|---|
Revenue | EUR 0.05bn | about EUR 22.4bn | about USD 19.7bn | about USD 4.0bn |
Revenue growth | +11% | — | — | — |
EBITDA / adjusted EBIT margin | 10.8% (EBITDA) | — | — | — |
R&D intensity | about 7% | — | — | — |
Recent Developments
All identified events are listed, including closely related parent (DMS Group) disclosures that directly affect EMS.
Not found in sources reviewed for the window: layoffs, litigation, or regulatory sanctions.



